Program
NWRD08
A development code. Also written as “NWRD08 administered by electroporation”.
Its studies are mostly in Squamous Intraepithelial Lesions, led by Newish Biotech (Wuxi).
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newish Biotech (Wuxi) | 32 open or running | phase 2since Sep 1, 2025 | May 23, 2023 | May 30, 2027phase 2 · NCT07175662 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2023First study: no phase study in HSIL of CervixFirst studyNCT05905354 · 12 planned · China
- Feb 18, 2024Phase 1 study in Squamous Intraepithelial LesionsNCT06276101 · 9 enrolled · China
- Sep 1, 2025Phase 2 study in Squamous Intraepithelial LesionsNCT07175662 · 150 planned · China
Ahead
- May 30, 2027Primary completion: phase 2 study in Squamous Intraepithelial LesionsNCT07175662
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07175662Squamous Intraepithelial Lesions · China | 2 | Recruiting | May 30, 2027 | 150 |
| NCT06276101Squamous Intraepithelial Lesions · China | 1 | Completed | Feb 19, 2025 | 9 |
| NCT05905354HSIL of Cervix · China | – | Recruiting | Jun 30, 2024 | 12 |
How it is read
Names in the registry
- “NWRD08 administered by electroporation”, 2 entries
- “NWRD08”, 1 entry
Codes read as this program: NWRD08.
Conditions, from the studies’ own filings
- Squamous Intraepithelial Lesions, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.